TRAINING UPDATE

Lab Location:FWMCDate Distributed:2/2/2023Department:Core LabDue Date:3/1/2023

DESCRIPTION OF PROCEDURE REVISION

Name of procedure:

Title: Rapid HIV- 1/2 Antibody Test (AHC.IM03)

Description of change(s):

FWMC: will begin using the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test Kit, In March of 2023. The current kit will be discontinued. WOMC and SGMC currently use the OraQuick test.

- Read the attached SOP for the new test
- Familiarize yourself with the patient log (AG-F163) and the external QC log (AG-F162)
- Take the MTS quiz
- See your supervisor to ensure you have received your hands-on training before 3/14/23
- Ensure that your training document is signed and submitted to your supervisor before 3/14/23

This SOP will be implemented at FWMC on March 14, 2022

Document your compliance with this training update by taking the quiz in the MTS system.

AHC.IM03 Rapid HIV-1/2 Antibody Test

Copy of version 5.0 (approved, not yet effective)

Periodic review not required

Uncontrolled Copy printed on 2/2/2023 2:35 PM

Effective Date 3/14/2023

Printed By Demetra Collier (110199)

Organization Fort Washington Medical Center

Approval and Periodic Review Signatures

Туре	Description	Date	Version	Performed By	Notes
Approval	Lab Director	1/30/2023	5.0	Senda Bellaifa Senda Beltaifa	

Approvals and periodic reviews that occurred before this document was added to the MediaLab Document Control system may not be listed.

Version History

Version	Status	Туре	Date Added	Date Effective	Date Retired
5.0	Approved, Not Yet Effective	Major revision	1/25/2023	3/14/2023	Indefinite
4.0	Retired	Major revision	2/13/2020	2/27/2020	Indefinite
Linked Doo	cuments	·	OFF	0.3	
			000)	
	F162 HIV External Quality Control L F163 HIV Patient Result Log	og			
· AG.	100 Thv Fallent Nesdit Log			ř O	
			C. L.	CA	
				Pa	
		In ari			
		C ₂ ,			

Linked Documents

- AG.F162 HIV External Quality Control Log
- AG.F163 HIV Patient Result Log

Adventist HealthCare

Site: Fort Washington Medical Center, Shady Grove Medical Center,

White Oak Medical Center

Title: Rapid HIV-1/2 Antibody Test

Technical SOP

Title	Rapid HIV-1/2 Antibody Test		
Prepared by	Ashkan Chini	Date:	2/20/2012
Owner	Robert SanLuis	Date:	2/20/2012

Laboratory Approval	Local Effective Date:	
Print Name and Title	Signature	Date
Refer to the electronic signature		
page for approval and approval		
dates.	5 .	

TABLE OF CONTENTS

date	es.	
TAD	Test Information	
IAB	BLE OF CONTENTS	
1.	Test Information	2
2.	Analytical Principle	2
3.	Specimen Requirements	2
4.	Reagents	3
5.	Calibrators/Standards	4
6.	Quality Control	4
7.	Equipment And Supplies	5
8.	Procedure	6
9.	Calculations	6
10.	Reporting Results And Repeat Criteria	6
11.	Expected Values	
12.	Clinical Significance	8
13.	Procedure Notes	8
14.	Limitations Of Method	9
15.	Safety	9
16.	Related Documents	9
17.	References	9
18.	Revision History	10
19.	Addenda	10

SOP ID: AHC.IM03 SOP Version # 4

CONFIDENTIAL: Authorized for internal use only

Page 1 of 10

Site: Fort Washington Medical Center, Shady Grove Medical Center,

White Oak Medical Center

1. TEST INFORMATION

Assay	Method/Instrument	Test Code
Rapid HIV-1/2 Antibody Test	Qualitative Immunoassay/Manual	HIVRS2

Title: Rapid HIV-1/2 Antibody Test

Synonyms/Abbreviations	
HIV-1/2 Antibody Test	

Department	
Core Lab/Immunology	

2. ANALYTICAL PRINCIPLE

An EDTA whole blood specimen is collected and transferred into the vial of developer solution, followed by the insertion of the test device. The developer solution facilitates the flow of the specimen into the device and onto the test strip. As the diluted specimen flows through the device, it rehydrates the protein-A gold colorimetric reagent contained in the device. As the specimen continues to migrate up the strip, it encounters the T zone. If the specimen contains antibodies that react with the antigens immobilized on the nitrocellulose membrane, a reddish-purple line will appear, qualitatively indicating the presence of antibodies to HIV-1 and/or HIV-2 in the specimen. The intensity of the line color is not directly proportional to the amount of antibody present in the specimen.

3. SPECIMEN REQUIREMENTS

3.1 Patient Preparation

Component	Special Notations	
Fasting/Special Diets	N/A	
Specimen Collection and/or Timing	Normal procedures for collecting and storing whole blood may be used for samples to be analyzed by this method.	
Special Collection Procedures	None	
Other	N/A	

3.2 Specimen Type & Handling

Criteria	
Type -Preferred	Whole blood (from EDTA tube only)
-Other Acceptable	None
Collection Container	EDTA (lavender top)
Volume - Optimum	4.0 mL
- Minimum	3.0 mL

Page 2 of 10

SOP ID: AHC.IM03 CONFIDENTIAL: Authorized for internal use only

SOP Version # 4

ncontrolled copy printed by Demetra Collier on 2/2/2023 2:35 PM (ES). Page 2 of 10

Adventist HealthCare

Site: Fort Washington Medical Center, Shady Grove Medical Center,

White Oak Medical Center

Criteria			
Transport Container and	Collection tube at room temperature		
Temperature			
Stability & Storage	Room Temperature /	5 days as whole blood	
Requirements	Refrigerated (2-30°C):		
	Frozen:	Not recommended	
Timing Considerations	N/A		
Unacceptable Specimens	Specimens that are unlabeled, improperly labeled, or those		
& Actions to Take	that do not meet the stated criteria are unacceptable.		
	Request a recollection and credit the test with the		
	appropriate LIS English text code for "test not performed"		
	message. Examples: Quantity not sufficient-QNS; Wrong		
	collection-UNAC. Document the request for recollection in		
	the LIS.		
Compromising Physical	Prior to testing, mix the blood tube gently by inversion		
Characteristics	several times to ensure a homogenous sample.		
Other Considerations	None		

Title: Rapid HIV-1/2 Antibody Test

Page 3 of 10

NOTE: Labeling requirements for all reagents, calibrators and controls include: (1) Open date, (2) Substance name, (3) Lot number, (4) Dice of preparation, (5) Expiration date, (6) Initials of tech, and (7) Any special storage instructions. Check all for visible signs of degradation.

4. REAGENTS

The package insert for a new lot of kits must be reviewed for any changes before the kit is used. A current Package Insert is included as a Related Document.

4.1 Reagent Summary

Reagents	Supplier & Catalog Number
OraQuick ADVANCE® Rapid HIV-1/2	OraSure Technologies, Inc.
Antibody Test Kit	Cat. No. 1001-0079

4.2 Reagent Preparation and Storage

Assay Kit	
Reagent	OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test Kit, every Pouch contains one each of following: Test Device, Developer Solution Vial and Absorbent Packet.
Container	Manufactured vial
Storage	Store at 2-27°C
Stability	Test Kit is stable until expiration date stamped on the cover.

SOP ID: AHC.IM03 CONFIDENTIAL: Authorized for internal use only

SOP Version # 4

Adventist HealthCare

Site: Fort Washington Medical Center, Shady Grove Medical Center,

White Oak Medical Center

Title: Ra	pid HIV-1/2 Antibo	dy Test

Preparation	If refrigerated, allow Test Kit to come to operating temperature before use (15-37°C).
	Once the Pouch is opened the Test Device must be inserted into
	the Developer Solution Vial within 60 minutes after introducing
	venipuncture whole blood.

5. CALIBRATORS/STANDARDS

N/A

6. QUALITY CONTROL

6.1 **Controls Used**

Cortrols	Supplier				
OraQuick ADVANCE® Rapid HIV-1/2	OraSure Technologies, Inc.				
Antibody Test Kit Controls	Cat. No. 1001-0077				
Control Preparation and Storage					

6.2

Assay Kit	OraQuick ADVANCE Papid HIV-1/2 Antibody Test Kit Controls	
Reagent 1	HIV-1 Positive Control	
Reagent 2	HIV-2 Positive Control	
Reagent 3	Negative Control	
Container	Manufactured vial	
Storage	Store at 2-8°C	
Stability	Stable until expiration date stamped on the reagent.	
Preparation	None	

6.3 **Frequency**

The kit has a built-in procedural (internal) control that demonstrates assay validity. It is run with each test performed.

The External Quality Control is run under the following circumstances:

- When a new lot or shipment of test kits is received or every 30 days, whichever is more frequent.
- If the temperature of the test kit storage area falls outside of 2-27°C.
- If the temperature of the testing area falls outside of 15-37°C.

CONFIDENTIAL: Authorized for internal use only SOP ID: AHC.IM03 SOP Version # 4 Page 4 of 10

Site: Fort Washington Medical Center, Shady Grove Medical Center,

White Oak Medical Center

Title: Rapid HIV-1/2 Antibody Test

Page 5 of 10

6.4 Tolerance Limits and Criteria for Acceptable QC

Internal Control:

The OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test Kit has a built-in procedural control that demonstrates assay validity. A reddish-purple line in the control ("C") area of the Result Window indicates that a specimen was added and that the fluid migrated appropriately through the test device. The control line will appear on all valid tests, whether or not the sample is reactive or non-reactive.

External Controls:

The HIV-1 and HIV-2 Positive Controls will produce a reactive test result and have been manufactured to produce a very faint test ("T") line.

The Negative Control will produce a non-reactive test result.

IF the QC result is	THEN
Invalid (refer to section 10.1)	Repeat the QC using a new Pouch
Invalid after repeat using a new Pouch	Repeat the QC using a new Pouch and set of External QC.
Invalid after repeat using External QC	Notify supervisor. Do not report patient results until acceptable QC results are obtained.

6.5 Documentation

Quality Control is documented on the HIV External Quality Control Log or HIV Patient Result Log as appropriate.

6.6 Quality Assurance Program

- Quality Control cross-checks must be done on each new batch of lot numbers received.
- The laboratory participates in CAP proficiency testing.

7. EQUIPMENT and SUPPLIES

7.1 Assay Platform

N/A

7.2 Equipment

Timer

7.3 Supplies

SOP Version #

- Reusable Test Stands
- Specimen Collection Loop

SOP ID: AHC.IM03 CONFIDENTIAL: Authorized for internal use only

Site: Fort Washington Medical Center, Shady Grove Medical Center,

White Oak Medical Center

8. PROCEDURE

NOTE: For all procedures involving specimens, buttoned lab coats, gloves, and face protection are required minimum personal protective equipment. Report all accidents to your supervisor.

Title: Rapid HIV-1/2 Antibody Test

8.1	Test Run
1.	Pick up an unused Specimen Collection Loop by the thick handle end. Put the rounded end of the loop into the tube of well mixed whole blood. Make sure that the loop is completely filled with blood with no bubbles.
2.	Immediately insert the blood-filled end of the loop all the way into the Vial. Use the loop to stir the blood sample in the Developer Solution. Remove the used loop from the solution. Throw the used loop away in a biohazard waste container.
3.	Check the Solution to make sure that it appears pink. This means that the blood was correctly mixed in 5 the Solution.
4.	Remove the Device from the Pouch. Check to make sure that an absorbent packet is included with the Device. If no absorbent packet is present, discard the Device and obtain a new Pouch for testing
5.	Insert the Flat Pad of the Device all the way into the Vial containing the blood sample. Make sure that the Flat Pad touckes the bottom of the Vial. The result window should be facing towards you.
6.	Start timing the test. Do not remove the Device from the Vial during the test. Read the results after 20 minutes but not more than 40 minutes in a fully lighted area. Record results on appropriate log; include stores and testing area temperatures.
	Record results on appropriate log; include storage and testing area temperatures.

NOTE: In the event that the test system becomes inoperable, notify supervision or designee for further direction. Patient specimens must be stored in a manner that maintains the integrity of the specimen.

9. CALCULATIONS

Not applicable

10. REPORTING RESULTS AND REPEAT CRITERIA

10.1 Interpretation of Data

Test Results	Location	Appearance
Reactive	ve Triangle Labeled C Reddish-Purple Line appears	
	Triangle Labeled T	Reddish-Purple Line appears
Non-reactive Triangle Labeled C Reddish-Purple Line appears		Reddish-Purple Line appears
	Triangle Labeled T	Blank
Invalid Triangle Labeled C Bla		Blank
	Triangle Labeled T	Blank or Reddish-Purple Line appears

SOP ID: AHC.IM03 CONFIDENTIAL: Authorized for internal use only

SOP Version # 4 Page 6 of 10

Site: Fort Washington Medical Center, Shady Grove Medical Center,

White Oak Medical Center

Title: Rapid HIV-1/2 Antibody Test

10.2 Rounding

N/A

10.3 Units of Measure

N/A

10.4 Clinically Reportable Range (CRR)

N/A

10.5 Review Patient Data

Review patient results for unusual patterns, trends or distributions, such as an unusually high percentage of abnormal results.

10.6 Repeat Criteria and Resulting

IF the result is	TEN
Invalid	Repeat the test using a new Pouch
Invalid after repeat using a new Pouch	Request a new specimen and repeat. Also run the external QC with patient specimen to ensure proper performance of the test.

IF the result is	THEN
Nonreactive	Report in LIS with code NR
Reactive	Report in LIS with code REAC. Confirmatory test is reflexed, label prints (test code XHIV4G)

Use LIS function **MEM** to enter results.

Enter Shift: (1, 2, or 3)

Worksheet: Use WUR3 for WOMC, SUR3 for SGMC or FMAN for FWMC.

Test: <Enter>

Enter "A" (Accept)

Enter Accession number

Press <Enter> until Result screen is displayed

Enter Results using above codes

Note: Results of tests performed for exposures are called to Occ Health during business hours and after hours to the nursing administrator.

SOP ID: AHC.IM03 CONFIDENTIAL: Authorized for internal use only SOP Version # 4 Page 7 of 10

Adventist HealthCare

Site: Fort Washington Medical Center, Shady Grove Medical Center,

White Oak Medical Center

Title: Rapid HIV-1/2 Antibody Test

11. EXPECTED VALUES

11.1 Reference Ranges

Nonreactive

11.2 Critical Values

None established

11.3 Standard Required Messages

Each result will have the following comment automatically added to the report by the LIS:

The OraQuick HIV-1 and 2 assay is intended for use as a rapid SCREENING test for the presence of HIV-1 a.c. 2 antibodies in whole blood plasma. Positive results must be confirmed with the CDC Recommended Laboratory HIV Testing Algorithm beginning with an HIV 1/2 and 2 m/antibody immunoassay. Negative screen tests indicate that no antibody to HIV 1 and 2 was detected. Patients exposed to high risk activity in the past three months may be falsely negative.

12. CLINICAL SIGNIFICANCE

Acquired Immune Deficiency Syndrome (AIDS), AIDS related complex (ARC) and pre-AIDS are thought to be caused by the Human Immunodeficiency Virus (HIV). The first AIDS-related virus, HIV-1 has been isolated from patients with AIDS and from healthy persons at high risk of AIDS. Genetic analysis of HIV-1 isolates has documented the existence of subtypes. Eight HIV-1 subtypes (A through H) have been identified worldwide. HIV-2 has been shown to share a number of conserved sequences with HIV-1, but serological cross-reactivity between HIV-1 and HIV-2 has been shown to be highly variable from sample to sample.

13. PROCEDURE NOTES

• FDA Status: FDA Approved/Cleared (waived)

• Validated Test Modifications: None

- Clinical data has not been collected to demonstrate performance of OraQuick HIV 1/2 antibody test in persons under 12 years of age.
- Individuals infected with HIV-1 or HIV-2 who are receiving highly active antiretroviral therapy (HAART) may produce false negative results.
- Individuals undergoing preventive treatment for HIV may produce false negative results.

SOP ID: AHC.IM03 CONFIDENTIAL: Authorized for internal use only SOP Version # 4

Site: Fort Washington Medical Center, Shady Grove Medical Center,

White Oak Medical Center

Title: Rapid HIV-1/2 Antibody Test

14. LIMITATIONS OF METHOD

14.1 Analytical Measurement Range (AMR) / Precision

N/A

14.2 Interfering Substances

To assess the impact of unrelated medical conditions or interfering substances on the sensitivity of the OraQuick ADVANCE Rapid HIV-1/2 Antibody Test, 200 serum/plasma specimens from a variety of medical conditions unrelated to HIV-1 infection and 125 specimens with interfering substances were spiked with an HIV-1 positive specimen to give a level of reactivity in the low positive range. All spiked specimens gave reactive results.

14.3 Clinical Sensitivity/Specificity/Predictive Values

Test Group	Total Specimen	OraQuick ADVANCE Reactive	Licensed EIA Repeatedly Reactive	True Positive
AIDS	40//	40	40	40
Known HIV-1 positive	481	4 79	481	481
High-Risk	625	1 7	20	17
Total	1146	\$536	541	538

15. SAFETY

Refer to your local and corporate safety manuals and Safety Data Sheet (SDS) for detailed information on safety practices and procedures and a complete description of hazards.

16. RELATED DOCUMENTS

- Health Care Worker Exposure to Blood and Body Fluids, Post Exposure Prophylaxis Policy, AHC Corporate Policy Manual, AHC 2.167
- HIV Protocol, Shady Grove Medical Center, Perinatal Services, policy 101-05-046b
- Blood and Body Fluid Exposure Orders, Laboratory policy
- Current package insert OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test
- HIV Patient Result Log (AG.F163)
- HIV External Quality Control Log (AG.F162)

17. REFERENCES

1. Package Insert, OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test, Item # 3001-1215, revised 03/2016.

SOP ID: AHC.IM03 CONFIDENTIAL: Authorized for internal use only SOP Version # 4 Page 9 of 10

Site: Fort Washington Medical Center, Shady Grove Medical Center,

White Oak Medical Center

18. REVISION HISTORY

Version	Date	Section	Reason	Reviser	Approval
			Supersedes SGAH/WAH.IM02.000		
000	12/1/15	3.1	Remove plasma	L Barrett	R SanLuis
000	12/1/15	6.3	Change external QC frequency	L Barrett	R SanLuis
000	12/1/15	11.3	Move report comment from 10.5	L Barrett	R SanLuis
000	12/1/15	13	Add statements for those on treatment	L Barrett	R SanLuis
000	12/1/15	16	Move logs from section 19	L Barrett	R SanLuis
000	12/1/15	16	Update insert date	L Barrett	R SanLuis
000	12/1/15	Footer	version # leading zero's dropped due to new EDCS in use as of 10/7/13	L Barrett	R SanLuis
1	4/12/18	Header	Add WAH	L Barrett	R SanLuis
1	4/12/18	4,6	Renove individual section labeling instructions and add general one	L Barrett	R SanLuis
1	4/12/18	10.5	Review da moved from section 6	L Barrett	R SanLuis
1	4/12/18	10.6	Add detail for furction MEM & calling, update confirmatory test information	L Barrett	R SanLuis
1	4/12/18	11.3	Update to match confirmatory test	R Master	R SanLuis
1	4/12/18	15	Update to new standard wrding	L Barrett	R SanLuis
1	4/12/18	17	Update package insert date	L Barrett	R SanLuis
2	2/10/20	Header	Change WAH to WOMC	L Barrett	R SanLuis
2	2/10/20	8.1	Added recording temperature on log	L Barrett	R SanLuis
2	2/10/20	10.6	Removed calling charge RN from after-hours instruction	J. Barrett	R SanLuis
2	2/10/20	16	Updated hospital policies	L Barrett	R SanLuis
3	1/25/23	Header	Added FWMC	D Collier	R SanLuis
3	1/25/23	Section 10.6	Added FWMC	D Collier	R SanLuis
3	1/25/32	Footer	Changed SOP prefix to AHC	D Collier	R SanLuis

Title: Rapid HIV-1/2 Antibody Test

19. ADDENDA

None

SOP ID: AHC.IM03 CONFIDENTIAL: Authorized for internal use only SOP Version # 4 Page 10 of 10



HIV EXTERNAL QUALITY CONTROL LOG

Fort Washington Medical Center					
Germantown Emergency Center					
Shady Grove Medical Center					
White Oak Medical Center					

external Q	C performed (date): _	Next exte	ernal QC is due = Ma	onth	Circle day below			
2 3	4 5 6 7	8 9 10 11 12 13	3 14 15 16	17 18 19 20 21	22 23 24 25	26 27 28 29	30 3	
nal Contro	ol must be documented	d each time a test is run.	Res	sults:	le Extern	al QC Lot:		
		n each new lot or shipment or	every 30 days,	□ Unaccepta	able	Exp:		
chever is m	nore frequent.	70			_			
Lot Status	OraQuick Rapid HIV-1/2 Antibody Test Kit Controls	Result Reactive / Non-reactive	Kit Lot #7 Expire	Internal Control Purple reddish line Appears? Yes / No	Temperature of the test kit storage area (2 - 27°C)	Temperature of testing area (15 - 37°C)	Date Tech code	
Lot Number □	HIV-1 Positive Control	☐ Reactive (expected) ☐ Non-reactive***	Nor	☐ Yes (acceptable) ☐ No (troubleshoot)**	Temp:°C	Temp:°C		
New Lot Received	HIV-2 Positive Control	☐ Reactive (expected) ☐ Non-reactive***		☐ Yes (acceptable) ☐ No (noubleshoot)**	☐ Acceptable ☐ Out of range*	☐ Acceptable ☐ Out of range*		
New Shipment Received	Negative Control	☐ Reactive*** ☐ Non-reactive (expected)		☐ Yes (acceptable) ☐ No (troubleshoot)**				
Current Lot Number 30 day interval	HIV-1 Positive Control	☐ Reactive (expected) ☐ Non-reactive***		☐ Yes (acceptable) ☐ No (troubleshoot)**	Temp:°C ☐ Acceptable ☐ Out of range*	Temp:°C ☐ Acceptable ☐ Out of range*		
	HIV-2 Positive Control	☐ Reactive (expected) ☐ Non-reactive***		☐ Yes (acceptable) ☐ No (troubleshoot)**				
	Negative Control	☐ Reactive***		☐ Yes (acceptable)				
		☐ Non-reactive (expected)		☐ No (troubleshoot)**				
f the purple		ust the temperature first then t appear, repeat test using a not to SOP section 6.4			peat, refer to SOP se	ection 10.5		
d Taab		Date:		Supervisor:		Date:	ed 1/2023	



HIV PATIENT RESULT LOG

Fort Washington Medical Center
Germantown Emergency Center
Shady Grove Medical Center
White Oak Medical Center

Internal Control must be documented each time a test is run. Verify external QC was performed at required interval with acceptable results***

Date	Patient Name & MR#	Patient Result Reactive / Non-reactive	Kit Lot # / Expire	Internal Control Purple reddish line Appears? Yes / No	Temperature of the test kit storage area (2 - 27°C)	Temperature of testing area (15 - 37°C)	Ext. QC verified Y/N	Tech Code
		Reactive		Yes (acceptable)	°C	°C		
		☐ Non-reactive	Tired	☐ No (troubleshoot)**	☐ Acceptable ☐ Out of range*	☐ Acceptable ☐ Out of range*		
		☐ Reactive	0,1	☐ Yes (acceptable)	°C	°C		
		☐ Non-reactive	6	☐ No (troubleshoot)**	☐ Acceptable ☐ Out of range*	☐ Acceptable ☐ Out of range*		
		☐ Reactive		Yes (acceptable)	°C □ Acceptable	°C ☐ Acceptable		
		☐ Non-reactive		☐ No (troubleshoot)**	☐ Out of range*	☐ Out of range*		
		☐ Reactive		☐ Yes (acceptable)	°C □ Acceptable	°C □ Acceptable		
		☐ Non-reactive		☐ No (troubleshoot)**	☐ Out of range*	☐ Out of range*		
		Reactive		☐ Yes (acceptable)	°C □ Acceptable	°C □ Acceptable		
		☐ Non-reactive		☐ No (troubleshoot)**	☐ Out of range*	☐ Out of range*		
		Reactive		☐ Yes (acceptable)	°C □ Acceptable	°C □ Acceptable		
		☐ Non-reactive		☐ No (troubleshoot)**	☐ Out of range*	☐ Out of range*		
Weekly re			Weekly review:		Weekly review:			
Weekly re	eview:		Weekly review:		Monthly review	:		

AG.F163.3 Revised 1/2023

^{*} If temperature is Out of Range, adjust the temperature first then repeat test with external quality control. Refer to SOP section 6.3

^{**} If the purple-reddish line does not appear, repeat test using a new pouch. If it stills fails, refer to SOP section

^{***} External QC required with every new lot or shipment, or every 30 days (whichever is more frequent) and if either temperature is out of range.